Q2 2026

Filed Aug 14, 2026 · 10-Q · 45 days after period end · 0001213900-26-090173

Q2 2026 · 10-Q

Revenue

$948.34K

−7.5% vs Q2 2025

Net Income

-$1.46M

N/M vs Q2 2025

EPS Diluted

-$0.04

N/M vs Q2 2025

Gross Profit$83,566N/M

Operating Income

Same quarter

Metric	Q2 2026	Q2 2025	Q2 2024	Q2 2023
Revenue	$948.34K	$1.03M	$924.94K	$1.10M
Net Income	-$1.46M	-$528.37K	-$1.44M	-$593.03K
EPS Diluted	-$0.04	-$0.16	-$0.89	-$0.35

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR